Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;15(3):184-191.
doi: 10.1007/s13181-019-00697-z. Epub 2019 Feb 11.

Adverse Effects of Physostigmine

Ann M Arens  1   2 , Tom Kearney  3   4
Affiliations
Review

Adverse Effects of Physostigmine

Ann M Arens et al. J Med Toxicol. 2019 Jul.

Erratum in

Abstract

Introduction: Physostigmine is a tertiary amine carbamate acetylcholinesterase inhibitor. Its ability to cross the blood-brain barrier makes it an effective antidote to reverse anticholinergic delirium. Physostigmine is underutilized following the publication of patients with sudden cardiac arrest after physostigmine administration in patients with tricyclic antidepressant (TCA) overdoses. We completed a narrative literature review to identify reported adverse effects associated with physostigmine administration.

Discussion: One hundred sixty-one articles and a total of 2299 patients were included. Adverse effects occurred in 415 (18.1%) patients. Hypersalivation (206; 9.0%) and nausea and vomiting (96; 4.2%) were the most common adverse effects. Fifteen (0.61%) patients had seizures, all of which were self-limited or treated successfully without complication. Symptomatic bradycardia occurred in 8 (0.35%) patients including 3 patients with bradyasystolic arrests. Ventricular fibrillation occurred in one (0.04%) patient with underlying coronary artery disease. Of the 394 patients with TCA overdose, adverse effects were described in 14 (3.6%). Adverse effects occurred in 7.7% of patients treated with an overdose of an anticholinergic agent compared with 20.6% of patients with non-anticholinergic agents. Five (0.22%) fatalities were identified.

Conclusions: In conclusion, significant adverse effects associated with the use of physostigmine were infrequently reported. Seizures were self-limited or resolved with benzodiazepines, and all patients recovered neurologically intact. Physostigmine should be avoided in patients with QRS prolongation on EKG, and caution should be used in patients with a history of coronary artery disease and overdoses with QRS prolonging medications. Based upon our review, physostigmine is a safe antidote to treat anticholinergic overdose.

Keywords: Antidote; Antimuscarinic; Delirium; Physostigmine; Review.

PubMed Disclaimer

Conflict of interest statement

None.

References

    1. Pentel P, Peterson CD. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9(11):588–590. doi: 10.1016/S0196-0644(80)80232-0. - DOI - PubMed
    1. Watkins JW, Schwarz ES, Arroyo-Plasencia AM, Mullins ME. Toxicology Investigators Consortium i. The use of physostigmine by toxicologists in anticholinergic toxicity. J Med Toxicol. 2015;11(2):179–184. doi: 10.1007/s13181-014-0452-x. - DOI - PMC - PubMed
    1. Burns MJ, Linden CH, Graudins A, Brown RM, Fletcher KE. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2000;35(4):374–381. doi: 10.1016/S0196-0644(00)70057-6. - DOI - PubMed
    1. Triggle DJ, Mitchell JM, Filler R. The pharmacology of physostigmine. CNS Drug Reviews. 1998;4(2):87–136. doi: 10.1111/j.1527-3458.1998.tb00059.x. - DOI
    1. Rumack BH. Anticholinergic poisoning: treatment with physostigmine. Pediatrics. 1973;52(3):449–451. - PubMed

Substances

LinkOut - more resources